(Total Views: 529)
Posted On: 12/19/2022 5:51:34 PM
Post# of 154852
MDGL is definitely interesting. Looks like they didn’t have a partner for their NASH trials. If they get approved BP missed on a big opportunity for a market share on possibility the first drug approved for NASH.
One article said even a 5 percent cut from MDGL could be 8.5 billion per year ? That seems absurd? I miss quote the article? I’ll have to double check.
Anyways they also reduced liver fibrosis. Perfect imo. This just shows if we get the drug to market in 4 years we will still be looking at billions in revenue. I’m assuming MDGL is still about a year out from approval unless they get an RTF.
One article said even a 5 percent cut from MDGL could be 8.5 billion per year ? That seems absurd? I miss quote the article? I’ll have to double check.
Anyways they also reduced liver fibrosis. Perfect imo. This just shows if we get the drug to market in 4 years we will still be looking at billions in revenue. I’m assuming MDGL is still about a year out from approval unless they get an RTF.
(2)
(0)
